Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Aragon Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on the treatment of hormone-resistant cancers, with an intital focuse on prostate and breast cancer, closed a $42M Series C financing. Participants include Aisling Capital, OrbiMed, Column Group and Topspin Partners. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Roka BioScience (Warren, NJ) a development-stage diagnostic company focused on molecular assays for monitoring food safety applications and biopharmaceutical manufacturing, closed a $27.5M Series D financing. Participants include Aisling Capital, OrbiMed, New Enterprise Associates and TPG Biotech.

Arteaus Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on antibody treatment for the prevention of migraine headache, closed a $18M Series A financing. Participants include Atlas Venture and OrbiMed.

Dfine (San Jose, CA) a commercial-stage medical device company focused on minimally invasive therapeutic devices used to treat pathologies of the vertebrae, closed a $25 million Series E financing. Participants include OrbiMed, Prospect Venture Partners, Split Rock Partners, BBT Capital, Highland Capital Management and Vanguard Ventures.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

arGEN-X (Netherlands) a preclinical-stage biopharmaceutical company focused on a monoclonal antibody platform for autoimmunity, inflammation and oncology, closed a $37M Series B financing. Participants include Orbimed, Seventure, Credit Agricole Private Equity, Forbion Capital Partners, Life Science Partners, BioGeneration Ventures, Erasmus MC Biomedical Fund, Thuja Capital Healthcare and VIB.

Enobia Pharma (Canada) a clinical-stage biotech company focused on hypophosphatasia, closed a $40M Series D financing. Participants include OrbiMed, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners. Thanx for your patience as we catch-up.

Ambit Biosciences (San Diego, CA) a clinical-stage biopharmaceutical company focused on kinase inhibitors for the treatment of cancer and other conditions, closed a $30M Series D financing. Participants include Apposite Capital, Perseus-Soros Biopharmaceutical Fund, OrbiMed, Forward Ventures, Roche Venture Fund, MedImmune Ventures, Gimv, GrowthWorks, GeneChem, Radius Ventures and NovaQuest Capital Management. The 2Q11 OnBioVC Trend [...]

Crown Bioscience (Santa Clara, CA) a commercial-stage oncology focused clinical research organization, closed a $28.8M Series C financing. Participants include OrbiMed, Argonaut Private Equity, and CDIB Capital Investment.

Glaukos (Laguna Hills, CA) a clinical-stage ophthalmology medical device company focused on the management of open-angle glaucoma, closed a $29.5M Series E. Participants include OrbiMed, Frazier Healthcare Ventures, InterWest Partners, Domain Associates and Versant Ventures.

Bonovo Orthopedics (Scottsdale, AZ) a commercial-stage medical device company focused on a diverse platform of spine and joint products, closed a $10M Series C financing. Participants include OrbiMed and Legend Capital.

SuperDimesnion (Minneapolis, MN) a commercial-stage medical device company focused on minimally invasive distal lung disease treatments, closed a $9.8M Series B financing. Participants include Dan Sullivan Investments, Medica Venture Partners, OrbiMed, Oxford Biosciences Partners and Pitango Venture Capital.

Cerenis Therapeutics (France), a clinical-stage biopharmaceutical company focused on the regression of atherosclerotic plaque and the enhancement of HDL function, closed a $40M Series C financing. Participants include Fund for Strategic Investment, Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed and DAIWA Corporate Investment.

« Previous Entries  Next Page »

to top of page...